🔍

MEDPLUS - Medplus Health

📊 NSE: MEDPLUS 🏢 Trading 📅 Last Updated: 12/14/2025 9:46

📢 Recent Corporate Announcements

MedPlus Subsidiary Faces 5-Day Drug License Suspension in Karnataka; Revenue Impact ₹1.77 Lakhs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 17 Mar 2026, 06:27 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at a store in Lingaraj Nagar, Karnataka. The suspension, issued by the Drugs Control Administration of Hubli Circle, is effective for five days following violations under Rule 65 of the Drugs and Cosmetics Act. The company estimates the financial impact to be a potential revenue loss of approximately ₹1.77 lakhs. While the financial impact is minimal, it highlights regulatory oversight on pharmacy operations.

Drug license suspended for 5 days at a store in Lingaraj Nagar, Karnataka
Action taken by Assistant Director, Drugs Control Administration, Hubli Circle
Violation cited under Rule 65 of the Drugs and Cosmetics Act, 1940
Estimated potential revenue loss quantified at ₹1.77 lakhs

💡 This is a minor operational issue affecting a single store with negligible impact on consolidated financials. No immediate action is required, though investors should monitor for any patterns of regulatory non-compliance across the store network.

MedPlus to Incorporate Wholly Owned Subsidiary for CSR Activities

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 16 Mar 2026, 06:55 PM

MedPlus Health Services Limited has announced that its Board of Directors approved the incorporation of a new Wholly Owned Subsidiary (WOS) on March 16, 2026. This entity will be established as a Section 8 company under the Companies Act, 2013, which is a non-profit structure. The primary objective of this subsidiary is to exclusively manage and undertake the company's Corporate Social Responsibility (CSR) activities. MedPlus will maintain 100% control and ownership of the new entity through cash subscription at face value.

Board approved the formation of a Section 8 Wholly Owned Subsidiary on March 16, 2026.
The new entity is dedicated exclusively to undertaking the company's CSR initiatives.
MedPlus Health Services Limited will hold 100% shareholding in the subsidiary.
Subscription to the share capital will be made in cash at face value.

💡 This is a routine administrative and governance-related update with no direct impact on the company's financial performance. Investors should remain focused on the company's core pharmacy retail operations and expansion metrics.

Medplus Subsidiary Store in Karnataka Faces 2-Day License Suspension; ₹2.88 Lacs Revenue Impact

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 15 Mar 2026, 06:38 PM

Medplus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at a single store in Bidadi, Karnataka. The suspension is effective for two days due to alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940. The company anticipates a minor financial impact with a potential revenue loss of approximately ₹2.88 lacs. This is a localized regulatory action and does not affect the company's broader operations or consolidated financial health.

Drug license suspended for 2 days at the Bidadi Bus stand store in Karnataka.
Order issued by the Assistant Director, Drugs Control Administration, Bangalore South Circle.
Estimated potential revenue loss is quantified at ₹2.88 lacs.
Action taken due to alleged contravention of Rule 65 of the Drugs and Cosmetics Rules, 1945.
The suspension order was received by the company on March 14, 2026.

💡 This is a minor regulatory event with negligible financial impact; investors should treat it as a routine operational disclosure. No change in investment thesis is warranted based on this specific store-level suspension.

MedPlus Subsidiary Faces Drug License Suspensions for 3 Stores; Revenue Impact ₹4.79 Lacs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 14 Mar 2026, 02:31 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received drug license suspension orders for three stores across Karnataka, Telangana, and Andhra Pradesh. The suspensions are temporary, ranging from two to seven days, due to violations under the Drugs and Cosmetics Act, 1940. The total estimated revenue loss from these suspensions is approximately ₹4.79 lacs. While the financial impact is negligible compared to the company's overall operations, it reflects strict regulatory oversight in the pharmacy retail segment.

Drug license suspensions issued for three stores located in Ramanagar (Karnataka), Dilsukhnagar (Telangana), and Penuganchiprolu (Andhra Pradesh).
Total potential revenue loss across all three locations is estimated at ₹4.79 lacs.
Suspension durations vary by location: 2 days for Ramanagar, 3 days for Dilsukhnagar, and 7 days for Penuganchiprolu.
The orders were issued by the respective state Drugs Control Administrations under Rule 65 of the Drugs and Cosmetics Act, 1940.

💡 No immediate action is required as the financial impact is immaterial to the company's consolidated financials. Investors should treat this as a routine regulatory update but monitor for any systemic compliance issues across the store network.

MedPlus Subsidiary Store in Odisha Faces 3-Day License Suspension; Revenue Impact ₹1.38 Lakhs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 10 Mar 2026, 05:48 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at a store in Baragarh, Odisha. The suspension is for a period of three days following an order from the Deputy Drugs Controller, Sambalpur. The action was taken due to alleged violations of Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates the total financial impact of this suspension to be a revenue loss of approximately ₹1.38 lakhs.

Drug license of a store in Baragarh, Odisha, suspended for a duration of 3 days
Action initiated by the Deputy Drugs Controller, Western Zone, Sambalpur
Alleged violation of Rule 65 of the Drugs and Cosmetics Act, 1940
Estimated potential revenue loss quantified at ₹1.38 lakhs
Order received by subsidiary Optival Health Solutions on March 9, 2026

💡 No immediate action is required as the financial impact is immaterial to the company's overall operations. Investors should view this as a minor localized regulatory issue.

MedPlus Subsidiary Faces 7-Day Drug License Suspension for Pune Store; ₹3.85 Lakh Revenue Impact

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 04 Mar 2026, 12:34 PM

MedPlus Health Services' subsidiary, Optival Health Solutions, has received a suspension order for the drug license of its store located in Sangvi, Pune. The suspension, issued by the FDA Maharashtra, is effective for seven days due to violations of Rule 65 of the Drugs and Cosmetics Act. The company has quantified the potential revenue loss at approximately ₹3.85 lakhs. While the financial impact is negligible on a consolidated basis, it reflects localized regulatory enforcement actions.

Drug license for the Sangvi, Pune store suspended for a period of 7 days
Estimated potential revenue loss during the suspension period is ₹3.85 lakhs
Action taken by the Assistant Commissioner & Licensing Authority, FDA Pune, Maharashtra
Suspension based on alleged violations of Rule 65 of the Drugs and Cosmetics Rules, 1945

💡 This is a minor regulatory event with no material impact on the company's overall valuation. Investors should monitor if such compliance issues become frequent across multiple locations.

MedPlus Subsidiary Receives One-Day Drug License Suspension for Telangana Store

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 28 Feb 2026, 06:23 PM

MedPlus Health Services Limited has informed that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at a single store in Kuntloor, Telangana. The suspension, issued by the Drugs Control Administration of Rangareddy, is for a duration of only one day. The action was taken due to alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a negligible financial impact with a potential revenue loss of approximately Rs 0.42 lacs.

One-day suspension of drug license for a store located in Kuntloor, Telangana
Action initiated by the Assistant Director, Drugs Control Administration, Rangareddy
Violation cited under Rule 65 of the Drugs and Cosmetics Act, 1940
Estimated potential revenue loss is minimal at Rs 0.42 lacs

💡 No action is required as the financial impact is immaterial to the company's consolidated operations. This is a minor regulatory compliance matter at a single retail outlet.

Medplus Health Services to Attend Nirmal Bang Investor Conference on March 6, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Feb 2026, 05:31 PM

Medplus Health Services Limited has scheduled a virtual meeting with analysts and institutional investors for March 6, 2026, at 2:00 PM. The company will be participating in the Nirmal Bang Sector Specific Conference, represented by its Key Managerial Personnel. This interaction is a standard regulatory disclosure under SEBI (LODR) Regulations, 2015. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the session.

Virtual meeting scheduled with Nirmal Bang Sector Specific Conference on March 6, 2026.
The session is set to commence at 02:00 PM IST.
Key Managerial Personnel (KMP) will represent the company during the interaction.
Company confirms that no Unpublished Price Sensitive Information (UPSI) will be disclosed.

💡 No immediate action is required as this is a routine investor interaction. Investors may look for post-meeting transcripts or presentations on the company website for insights into management's outlook.

MedPlus Subsidiary Faces 7-Day License Suspension for Guntur Store; Revenue Impact ₹2.22 Lacs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 26 Feb 2026, 05:37 PM

MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a suspension order for its drug license at a store in Guntur, Andhra Pradesh. The suspension is effective for seven days following violations under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of approximately ₹2.22 lacs during this period. While the financial impact is negligible compared to the company's total revenue, it reflects ongoing regulatory compliance monitoring in the retail pharmacy sector.

Drug license for the SVN Colony Guntur store suspended for a period of 7 days
Order issued by the Drugs Control Administration, Guntur, Andhra Pradesh on February 25, 2026
Suspension due to alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940
Estimated potential revenue loss quantified at ₹2.22 lacs
Action taken against subsidiary Optival Health Solutions Private Limited

💡 This is a minor regulatory event with insignificant financial impact on the company's overall operations. Investors should treat this as a routine compliance matter and no immediate portfolio action is necessary.

MedPlus Seeks Shareholder Nod for ₹11,262.20 Mn Related Party Transaction with Subsidiary

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 24 Feb 2026, 09:39 PM

MedPlus Health Services has initiated a postal ballot to seek shareholder approval for material related party transactions (RPT) with its subsidiary, Optival Health Solutions Private Limited. The proposed transactions for the financial year 2026-27 are capped at an aggregate value of ₹11,262.20 million. This approval is mandatory under SEBI regulations as the transaction value exceeds 10% of the company's annual consolidated turnover. The e-voting period for shareholders is scheduled from February 25 to March 26, 2026.

Proposed RPT with material subsidiary Optival Health Solutions for FY 2026-27.
Aggregate transaction limit set at ₹11,262.20 million plus applicable taxes.
Transactions exceed the 10% materiality threshold of annual consolidated turnover.
Remote e-voting period runs from February 25, 2026, to March 26, 2026.
Board confirms transactions are in the ordinary course of business and at arm’s length.

💡 Investors should note this as a standard regulatory compliance procedure for large-scale inter-company operations; no immediate portfolio changes are recommended.

Medplus Subsidiary Store in Telangana Faces 3-Day License Suspension

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 23 Feb 2026, 05:38 PM

Medplus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a suspension order for its drug license at a single store in Telangana. The suspension, issued by the Drugs Control Administration, is for a duration of three days starting from the receipt of the order on February 22, 2026. The company cited a violation under Rule 65 of the Drugs and Cosmetics Act, 1940. The financial impact is negligible, with an estimated revenue loss of approximately ₹0.76 lacs.

Drug license for one store in Surya Nagar Colony Mallpur, Telangana, suspended for 3 days
Action taken by the Assistant Director, Drugs Control Administration, Shameerpet
Violation cited under Rule 65 of the Drugs and Cosmetics Act, 1940
Estimated potential revenue loss is minimal at ₹0.76 lacs

💡 No action is required as the financial impact is immaterial to the company's overall operations. This appears to be a routine localized regulatory matter.

MedPlus Subsidiary Faces Drug License Suspensions in Karnataka; Revenue Loss of ₹4.19 Lacs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 21 Feb 2026, 05:20 PM

MedPlus Health Services' subsidiary, Optival Health Solutions, has received suspension orders for drug licenses at two stores in Davanagere, Karnataka. The first store at Vinobha Nagar faces a 5-day suspension with a projected revenue loss of ₹1.40 lacs. The second store at KSRTC Davanagere faces a 7-day suspension with a projected revenue loss of ₹2.79 lacs. These actions were taken due to violations of Rule 65 of the Drugs and Cosmetics Act, 1940. While the financial impact is negligible relative to the company's total scale, it indicates localized regulatory oversight.

Suspension of drug licenses for two stores in Davanagere, Karnataka, due to Rule 65 violations.
Store at Vinobha Nagar suspended for 5 days with a potential revenue loss of ₹1.40 lacs.
Store at KSRTC Davanagere suspended for 7 days with a potential revenue loss of ₹2.79 lacs.
Total quantifiable financial impact estimated at a minor ₹4.19 lacs.
Orders were issued by the Assistant Director, Drugs Control Administration, Davanagere Circle.

💡 No immediate action is required as the financial impact is immaterial to the company's overall operations. Investors should monitor if such regulatory suspensions become a recurring pattern across more locations.

MedPlus Subsidiary Receives One-Day License Suspension for Karnataka Store; Revenue Impact ₹0.33 Lacs

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 20 Feb 2026, 04:51 PM

MedPlus Health Services Limited's subsidiary, Optival Health Solutions, has been ordered to suspend operations at one store in Tumkur, Karnataka, for a single day. The order, received on February 19, 2026, stems from violations of Rule 65 of the Drugs and Cosmetics Act. The company estimates a minimal revenue loss of approximately ₹0.33 lacs from this suspension. Such localized regulatory actions are common in the retail pharmacy sector and have no material impact on consolidated financials.

Drug license suspended for one day at the Koratagere store in Tumkur, Karnataka.
Action taken by the Drugs Control Administration under Rule 65 of the Drugs and Cosmetics Act.
Quantifiable financial impact is a negligible revenue loss of ₹0.33 lacs.
The order was officially received by the subsidiary on February 19, 2026.

💡 This is a minor operational event with no impact on the company's valuation. Investors can treat this as a routine regulatory compliance matter with no material consequence.

MedPlus Subsidiary Faces 7-Day Drug License Suspension for Andhra Pradesh Store

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 13 Feb 2026, 06:43 PM

MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a suspension order for the drug license of its store in Eluru, Andhra Pradesh. The suspension is for a period of seven days due to alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of approximately Rs 4.28 lacs during this period. While the financial impact is minimal, it highlights regulatory oversight on pharmacy operations.

Drug license suspended for 7 days at the Eluru store in West Godavari District, Andhra Pradesh
Action initiated by the Drugs Control Administration under Rule 65 of Drugs and Cosmetics Rules
Estimated potential revenue loss quantified at Rs 4.28 lacs
Order received on February 12, 2026, affecting subsidiary Optival Health Solutions Private Limited

💡 No immediate action is required as the financial impact is negligible compared to the company's total revenue. Investors should treat this as a routine regulatory update but monitor for any pattern of recurring compliance issues.

MedPlus Subsidiary Faces 15-Day Drug License Suspension for Pune Store; ₹6.27 Lakh Revenue Impact

🔴 NEGATIVE ⭐ 3/10

REGULATORY 📅 04 Feb 2026, 05:57 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for the drug license of its store located in Sasanenagar, Pune. The suspension is effective for 15 days following an order from the Food & Drug Administration, Maharashtra, due to violations under Rule 65 of the Drugs and Cosmetics Act. The company estimates a potential revenue loss of approximately ₹6.27 lakhs during this period. While the financial impact is minor, it highlights ongoing regulatory oversight in the pharmacy retail sector.

15-day drug license suspension for a specific store in Sasanenagar, Pune, Maharashtra
Estimated potential revenue loss of ₹6.27 lakhs due to the temporary closure
Action taken by the Assistant Commissioner & Licensing Authority, FDA, Maharashtra
Violation cited under Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945
Order received on February 3, 2026, and disclosed on February 4, 2026

💡 The financial impact is immaterial to the company's consolidated financials; however, investors should monitor for any patterns of regulatory non-compliance across other store locations.

View All MEDPLUS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 9.17% in FY 2025 to INR 61,846.69 million. By segment: Retail grew 8.6% to INR 60,268.86 million; Diagnostic services grew 44.3% to INR 1,081.07 million; and Other segments grew 15.4% to INR 10.60 million.

Geographic Revenue Split

The company operates 4,930 stores across 13 states and 1 union territory. In Q2 FY 2026, 68 net store additions were made beyond Tier-One cities, aligning with the strategy to deepen retail healthcare access in underserved markets.

Profitability Margins

Consolidated gross margin increased from 21.92% in FY 2024 to 24.37% in FY 2025, reaching a new high of 26.1% in Q2 FY 2026. This 240 bps YoY improvement is driven by the increasing share of high-margin private label products.

EBITDA Margin

Consolidated operating EBITDA for Q2 FY 2026 stood at 5.3% (INR 887 million). Mature outlets (older than 12 months) maintained a solid 11.8% store-level EBITDA margin, demonstrating strong unit economics upon store maturity.

Capital Expenditure

Not disclosed in absolute INR Cr; however, the company added 145 gross stores in Q2 FY 2026 and maintains a property bank of 400+ locations for future expansion.

⚙️ Operational Drivers

Raw Materials

Branded pharmaceutical products represent approximately 75% of sales. Private label pharmaceuticals and FMCG goods constitute 21.5% of total revenue as of Q2 FY 2026.

Capacity Expansion

Current network includes 4,930 stores covering 2.6 million+ square feet as of Q2 FY 2026. The company added 398 stores in FY 2025 and 117 net stores in Q2 FY 2026.

Raw Material Costs

Cost of goods sold was INR 46,406.61 million in FY 2025, representing 75.03% of total income, down from 77.52% in FY 2024 due to better supply chain efficiency.

Manufacturing Efficiency

The company utilizes a backward-integrated value chain and tech-driven inventory management to maintain cost efficiency across 48k+ SKUs in warehouses.

📈 Strategic Growth

Expected Growth Rate

6.50%

Growth Strategy

Growth will be driven by a cluster-based expansion strategy focusing on deeper penetration in 13 states, a pilot franchisee model, and increasing private label revenue share to 20-25%. The company is also expanding its diagnostics segment, which grew 44.3% in FY 2025.

Products & Services

Branded and private-label medicines, wellness products, FMCG goods, pathology and radiology diagnostic services, and insurance broking.

Brand Portfolio

MedPlus, MedPlus Mart, MedPlus Lens, MedPlus Labs.

New Products/Services

Private label pharma sales reached 12.1% of revenue in Q2 FY 2026, while non-pharma private labels contributed 9.6%.

Market Expansion

Expansion into Tier II and III cities to capitalize on rising health awareness and underserved retail healthcare markets.

Market Share & Ranking

2nd largest pharmacy retailer in India by revenue.

🌍 External Factors

Industry Trends

The Indian retail pharmacy industry is growing rapidly and moving toward consolidation and digital transformation. MedPlus is positioned as a pioneer in the organized retail format with a 19-year presence.

Competitive Landscape

Intense competition from both traditional unorganized retail pharmacies and well-funded online pharmacy platforms.

Competitive Moat

Durable advantages include a backward-integrated supply chain, a massive network of 4,900+ stores, and high customer stickiness (70% retention) through loyalty programs. These are sustainable due to the high capital requirement for competitors to build similar infrastructure.

Macro Economic Sensitivity

Sensitive to India's growing chronic disease burden and increasing internet penetration which drives ePharmacy (omnichannel) demand.

Consumer Behavior

Shift toward impulsive buying in the non-pharma/FMCG segment, where there is no doctor-prescribed dosage limit, driving higher basket values.

⚖️ Regulatory & Governance

Industry Regulations

Operations are heavily influenced by the Drug Pricing Control Order (DPCO) and compliance with various pharmaceutical retail and diagnostic licensing laws.

Legal Contingencies

No material changes, commitments, or insolvency proceedings were initiated during the financial year ended March 31, 2025.

⚠️ Risk Analysis

Key Uncertainties

Promoter share pledging is identified as a financial risk that affects investor confidence. Pharmacist attrition is an HR risk that could impact service quality.